Neoplat1 mg/ml

Established / FDA-Approved Uses

• Metastatic testicular tumors: Neoplat is indicated, in established combination chemotherapy regimens with other cytotoxic agents, for the treatment of metastatic testicular tumors in patients who have already received appropriate surgical and/or radiotherapeutic treatment.
• Metastatic ovarian tumors: Neoplat is indicated in combination with cyclophosphamide as first-line therapy for metastatic ovarian tumors, and as a single agent in patients with disease previously treated with standard surgical and chemotherapeutic modalities who have not received prior chemotherapy.
• Advanced bladder cancer: Neoplat is indicated as a single agent for transitional cell bladder cancer that is no longer amenable to local treatment (surgery and/or radiotherapy).

Guideline-Supported / Combination Uses (Broader Oncology Practice)

• Used as part of combination chemotherapy regimens for head and neck squamous cell carcinoma, based on oncology treatment guidelines.
• Used as part of combination chemotherapy (often with radiotherapy, i.e., chemoradiation) for cervical cancer.
• Used as part of combination chemotherapy regimens for non-small cell and small cell lung cancer.
• Used, under oncologist supervision, in combination regimens for other solid tumors such as esophageal and gastric cancer, based on established oncology practice rather than a specific product-label indication.

Neoplat is a highly toxic cytotoxic chemotherapy medicine and must only be prescribed, dispensed, and administered under the close supervision of a qualified oncologist experienced in the use of cancer chemotherapeutic agents, with adequate facilities for monitoring and managing toxicity.

Each mL of Cisplatin sterile injectable solution typically contains 1 mg of cisplatin as the active ingredient, together with sodium chloride and water for injection, with hydrochloric acid and/or sodium hydroxide used for pH adjustment. Cisplatin is also available in some markets as a sterile lyophilized powder for reconstitution. Exact strength (e.g., 10 mg, 50 mg, or 100 mg vials) and excipients may vary by manufacturer; check the product label for the specific formulation dispensed.

Neoplat is a platinum-based cytotoxic (heavy metal complex) antineoplastic agent, chemically related to the alkylating agents in its mechanism of action, used in the treatment of several solid tumors including testicular, ovarian, and bladder cancer. It is administered only as a slow intravenous infusion, always with intensive intravenous hydration, under close specialist supervision, because of its well-established potential for serious, dose-related toxicity, particularly to the kidneys, ears, and bone marrow.

Neoplat belongs to the therapeutic class of antineoplastic agents, specifically the platinum coordination complexes (platinum-based chemotherapy), a group of drugs that act through a DNA cross-linking mechanism similar in effect to classical alkylating agents.

Cisplatin is a heavy-metal coordination complex consisting of a central platinum atom surrounded by two chloride atoms and two ammonia molecules in the cis configuration. After intravenous administration, the chloride ligands undergo displacement (aquation) inside cells, where chloride concentration is low, generating highly reactive, positively charged platinum species. These reactive species bind covalently to nucleophilic sites on DNA, forming predominantly intrastrand cross-links between adjacent guanine bases. This cross-linking distorts the DNA helix, inhibits DNA replication and transcription, and triggers cell-cycle arrest and apoptosis, an effect that is not specific to the cell cycle phase and is similar in overall effect to the alkylating class of chemotherapy drugs. Cisplatin is extensively (over 90%) and irreversibly bound to plasma proteins. Free (unbound) platinum has a plasma half-life of approximately 20 to 30 minutes, but protein-bound platinum is eliminated very slowly, with a terminal half-life of several days, contributing to prolonged tissue retention. Elimination is primarily renal; renal impairment reduces clearance and increases systemic and tissue exposure, which is the pharmacologic basis for its dose-limiting nephrotoxicity.

Neoplat is given only by slow intravenous infusion in a hospital or specialized oncology infusion setting, never orally, intramuscularly, or subcutaneously, and never undiluted. It must always be preceded by adequate intravenous hydration and followed by post-hydration with monitored urine output, as described under Dosage and Administration. Neoplat should not be administered using aluminum-containing intravenous administration sets or needles, as aluminum reacts with Neoplat, causing precipitate formation and loss of potency. As a cytotoxic drug, Neoplat must be prepared and handled by trained personnel using appropriate protective equipment, with strict precautions to avoid skin, eye, or mucosal contact and to manage extravasation promptly, as it can cause severe local tissue injury if it leaks outside the vein.

Nephrotoxic Drugs (Aminoglycosides, Amphotericin B) – Major

Concurrent or sequential use of Neoplat with other nephrotoxic drugs such as aminoglycoside antibiotics or amphotericin B can produce additive kidney damage; such combinations should be avoided or used only with extreme caution and close renal monitoring.

Ototoxic Drugs (Loop Diuretics, Aminoglycosides)

Neoplat combined with other ototoxic agents, such as loop diuretics (e.g., furosemide) or aminoglycoside antibiotics, can increase the risk and severity of hearing loss and tinnitus through additive ototoxicity; concurrent use requires caution and audiometric monitoring.

Phenytoin and Other Anticonvulsants

Neoplat can reduce plasma phenytoin (and possibly other anticonvulsant) concentrations to subtherapeutic levels, potentially reducing seizure control; anticonvulsant levels should be monitored during and after Neoplat therapy.

Live Vaccines

Because Neoplat causes significant immunosuppression, administration of live or live-attenuated vaccines should be avoided during and for a period after treatment, due to the risk of disseminated vaccine-strain infection; consult the treating oncologist regarding vaccination timing.

Other Bone-Marrow-Suppressing Agents

Combining Neoplat with other myelosuppressive chemotherapy or radiotherapy increases the risk of severe bone marrow suppression; this is often intentional within a supervised combination regimen but requires intensive blood count monitoring.

Very Common

• Severe nausea and vomiting (highly emetogenic; occurs in almost all patients without adequate antiemetic prophylaxis)
• Nephrotoxicity (kidney impairment; see Precautions and Warnings)
• Myelosuppression: reduced white blood cells, red blood cells (anemia), and platelets
• Ototoxicity: tinnitus and high-frequency hearing loss (see Precautions and Warnings)
• Electrolyte disturbances: low magnesium, potassium, calcium, and sodium

Common

• Peripheral neuropathy (numbness, tingling in hands/feet), which may be irreversible with cumulative dosing
• Loss of appetite, taste changes, fatigue, and weakness
• Hiccups and mild liver enzyme elevations

Serious / Less Common

• Anaphylactic-like reactions (facial swelling, wheezing, rapid heartbeat, low blood pressure), which can occur within minutes of administration, especially on re-exposure
• Ocular toxicity (blurred vision, altered color perception, optic neuritis) with high-dose or prolonged therapy
• Local tissue injury or ulceration if the infusion leaks outside the vein (extravasation)
• Cardiovascular events, including thromboembolism, reported with Neoplat-based chemotherapy

Patients should seek prompt medical attention for fever, signs of infection, unusual bleeding or bruising, severe or persistent vomiting, ringing in the ears, reduced urination, numbness/tingling, or any signs of an allergic reaction during or shortly after a Neoplat infusion.

Neoplat is contraindicated during pregnancy. As a cytotoxic, DNA-damaging chemotherapy agent, Neoplat is mutagenic and has been shown to be teratogenic and embryotoxic in animal studies, and it can cause serious fetal harm. Women of childbearing potential should use effective contraception during treatment with Neoplat and for a period after completing treatment, and should avoid becoming pregnant. If pregnancy occurs during treatment, the patient should be informed of the potential hazard to the fetus and referred for immediate specialist evaluation.

Neoplat is also contraindicated during breastfeeding; it has been detected in human breast milk, and breastfeeding should be discontinued before starting and throughout treatment because of the risk of serious toxicity to a nursing infant.

Nephrotoxicity (Boxed-Warning-Level Risk)

Cumulative, dose-related kidney damage is a major, well-established toxicity of Neoplat and can be severe. Renal function (serum creatinine, BUN, creatinine clearance) and serum electrolytes must be assessed before treatment begins and before each subsequent course. Vigorous intravenous hydration before and after each dose (see Dosage and Administration), and avoidance of other nephrotoxic drugs where possible, are essential to reduce this risk; doses should be withheld or reduced if renal function is impaired.

Ototoxicity (Boxed-Warning-Level Risk)

Hearing loss, particularly in the high-frequency range, and tinnitus can occur and may be cumulative with repeated doses and irreversible; the risk is greater in children and with concurrent cranial irradiation or other ototoxic drugs. Audiometric testing is recommended before starting treatment, before each subsequent dose, and for long-term follow-up after completing therapy.

Severe Nausea and Vomiting

Neoplat is highly emetogenic; aggressive prophylactic antiemetic therapy (per current antiemetic guidelines) must be given before and after each dose to prevent severe acute and delayed nausea and vomiting, which can otherwise lead to dehydration and electrolyte disturbances.

Myelosuppression

Bone marrow suppression (low white cells, red cells, and platelets) is common and dose-related, with the nadir typically occurring 2 to 3 weeks after a dose. Complete blood counts must be monitored regularly, and treatment withheld or the dose reduced for significant myelosuppression, given the associated risk of serious infection and bleeding.

Anaphylactic-Like Reactions

Facial swelling, difficulty breathing (bronchoconstriction), rapid heartbeat, and low blood pressure can occur within minutes of Neoplat administration, particularly in previously treated patients. Resuscitation equipment and medications must be available whenever Neoplat is administered, and patients should be observed closely during and after each infusion.

Electrolyte Wasting

Neoplat commonly causes renal wasting of magnesium, potassium, and calcium, which may require electrolyte monitoring and supplementation before, during, and after treatment.

Peripheral Neurotoxicity and Ocular Toxicity

Peripheral sensory neuropathy can develop, particularly with higher cumulative doses or prolonged treatment, and may be irreversible; symptoms can appear or worsen weeks after the last dose. Visual disturbances, including rare optic neuritis, have also been reported; report any new or worsening numbness, tingling, or visual changes promptly.

General Handling and Adherence

Neoplat is a highly toxic cytotoxic drug and must be prepared, handled, and disposed of according to institutional hazardous-drug guidelines by trained personnel. Neoplat must be given exactly as prescribed and scheduled by the treating oncologist – doses, cycles, or combination regimens should never be changed, delayed, or shared with another person without direct medical advice, and every scheduled laboratory monitoring visit (renal function, blood counts, electrolytes, hearing tests) should be kept.

Overdose with Neoplat can cause severe, potentially fatal toxicity, including acute kidney failure, liver failure, profound and prolonged bone marrow suppression, severe and intractable nausea and vomiting, deafness, optic neuritis and other ocular toxicity, and peripheral neuritis. There is no specific antidote for Neoplat overdose, and hemodialysis is not effective once the drug has become protein-bound. If overdose is suspected, seek immediate medical attention or contact emergency services/poison control right away; management is supportive, under specialist (oncology/critical-care) supervision, and may include intensive monitoring and treatment of the resulting organ toxicities.

Store unopened Neoplat vials at controlled room temperature (20–25°C / 68–77°F), protected from light, and do not refrigerate, as refrigeration can cause the drug to precipitate out of solution. Keep out of reach of children. Once reconstituted or diluted for infusion, Neoplat solutions have limited stability, must be protected from light, must never be refrigerated, and should be used within the timeframe specified on the product label or by hospital pharmacy protocol; discard any unused portion as hazardous cytotoxic waste per institutional guidelines.

Renal Impairment

Neoplat is contraindicated in patients with pre-existing significant renal impairment (see Contraindications) and requires careful dose adjustment and monitoring in patients with lesser degrees of renal dysfunction (see Dosage and Administration and Precautions and Warnings).

Hepatic Impairment

No well-established dedicated dosing guidelines exist; use with caution and close monitoring under specialist supervision.

Elderly Patients

Elderly patients may be more susceptible to Neoplat-related nephrotoxicity, myelosuppression, and peripheral neuropathy, and are at greater risk of infectious complications; renal function should be monitored particularly closely in this group.

Pediatric Patients

Safety and efficacy of Neoplat in children have not been formally established in the same manner as in adults, although it is used in pediatric oncology protocols for specific childhood cancers under specialist supervision. Ototoxicity is more frequent and can be more severe in children; audiometric monitoring before, during, and for years after treatment is required (see Pediatric Uses).

Pregnancy and Lactation

See Pregnancy and Lactation – Neoplat is contraindicated in both.

Treatment with Neoplat is given in cycles, with the exact number, dose, and interval (commonly every 3 to 4 weeks, or over consecutive days per cycle for some testicular cancer regimens) determined by the treating oncologist based on the specific cancer, combination regimen, and the patient's response and tolerance. Treatment is generally continued for a protocol-defined number of cycles, or until disease progression, unacceptable toxicity (particularly cumulative nephrotoxicity, ototoxicity, or neurotoxicity), or completion of the planned curative or palliative course, as determined by the oncologist.

Where Neoplat is supplied as a sterile lyophilized powder for injection, it must be reconstituted with sterile water for injection to the concentration specified on the product label, then further diluted before infusion, typically in a suitable dextrose/saline vehicle (e.g., with mannitol) as described under Dosage and Administration. Reconstitution and dilution must be performed by trained pharmacy or oncology personnel using aseptic technique, avoiding any aluminum-containing needles, syringes, or administration sets, as aluminum reacts with Neoplat and causes precipitation and loss of potency. Once reconstituted/diluted, the solution must be protected from light, must not be refrigerated, and should be used within the stability period specified by the manufacturer or institutional pharmacy protocol.

Antineoplastic agent; platinum coordination complex (platinum-based chemotherapy); alkylating-like cytotoxic agent.

Cisplatin enters cells and undergoes intracellular activation (aquation) to form reactive, positively charged platinum species that bind covalently to DNA, forming predominantly intrastrand cross-links between adjacent guanine bases. These DNA cross-links distort the double helix, block DNA replication and transcription, and activate cellular damage-response pathways that lead to cell-cycle arrest and programmed cell death (apoptosis), particularly in rapidly dividing malignant cells.

D

Neoplat is used in pediatric oncology as part of specialist-directed combination chemotherapy protocols for certain childhood solid tumors, but formal safety and efficacy data in children are more limited than in adults, and it should only be used under the care of a pediatric oncologist. Ototoxicity with Neoplat is more common and can be more severe in children than in adults; all children must have audiometric (hearing) testing performed before starting treatment, before each subsequent dose, and for several years after completing therapy, given the risk of cumulative and irreversible hearing loss.